Hepatocellular cancer arises from loss of transforming growth factor beta signaling adaptor protein embryonic liver fodrin through abnormal angiogenesis

Hepatology

Volumn 48, Issue 4, 2008, Pages 1128-1137

  Baek, Hye Jung ^a   Lim, Sung Chul ^b   Kitisin, Krit ^c   Jogunoori, Wilma ^c   Tang, Yi ^c   Marshall, M Blair ^c   Mishra, Bibhuti ^c   Kim, Tae Hyun ^a   Cho, Kwan Ho ^a   Kim, Sang Soo ^a   Mishra, Lopa ^c,d  

^a National Cancer Center   (South Korea)

^b Chosun University   (South Korea)

^c GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; FODRIN; RETINOBLASTOMA PROTEIN; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA; ACTIN BINDING PROTEIN; CARRIER PROTEIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTERY ENDOTHELIUM; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STRAIN HEPG2; CONTROLLED STUDY; EMBRYO; ENDOTHELIUM; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LETHALITY; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STEM CELL; YOLK SAC; ANIMAL; CATTLE; CELL CYCLE; DISEASE MODEL; LIVER TUMOR; METABOLISM; MOUSE MUTANT; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROGNOSIS; TUMOR CELL LINE; VASCULAR ENDOTHELIUM;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CARRIER PROTEINS; CATTLE; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; HEPATOCYTES; HUMANS; LIVER NEOPLASMS; MICE; MICE, KNOCKOUT; MICROFILAMENT PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; RETINOBLASTOMA PROTEIN; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 54449089923     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22460     Document Type: Article

References (49)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153-156.
2. El-Serag HB. Hepatocellular carcinoma: Recent trends in the United States. Gastroenterology 2004;127:S27-S34.
3. Roberts LR, Gores GJ. Hepatocellular carcinoma: Molecular pathways and new therapeutic targets. Semin Liver Dis 2005;25:212-225.
4. Feitelson MA, Sun B, Satiroglu Tufan NL, Liu J, Pan J, Lian Z. Genetic mechanisms of hepatocarcinogenesis. Oncogene 2002;21:2593-2604.
5. Sun HC, Tang ZY. Angiogenesis in hepatocellular carcinoma: The retrospectives and perspectives. J Cancer Res Clin Oncol 2004;130:307-319.
6. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
7. Semenza GL. Angiogenesis in ischemic and neoplastic disorders. Annu Rev Med 2003;54:17-28.
8. Lien WH, Chen CK, Lai LY, Chen YH, Wu MP, Wu LW. Participation of cyclin D1 deregulation in TNP-470-mediated cytostatic effect: Involvement of senescence. Biochem Pharmacol 2004;68:729-738.
9. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-364.
10. Kaminska B, Wesolowska A, Danilkiewicz M. TGF beta signalling and its role in tumour pathogenesis. Acta Biochim Pol 2005;52:329-337.
11. Villanueva A, Garcia C, Paules AB, Vicente M, Megias M, Reyes G, et al. Disruption of the antiproliferative TGF-beta signaling pathways in human pancreatic cancer cells. Oncogene 1998;17:1969-1978.
12. Xu G, Chakraborty C, Lala PK. Expression of TGF-beta signaling genes in the normal, premalignant, and malignant human trophoblast: Loss of smad3 in choriocarcinoma cells. Biochem Biophys Res Commun 2001; 287:47-55.
13. Grady WM, Myeroff LL, Swinler SE, Rajput A, Thiagalingam S, Lutterbaugh JD, et al. Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers. Cancer Res 1999;59:320-324.
14. Woodford-Richens KL, Rowan AJ, Poulsom R, Bevan S, Salovaara R, Aaltonen LA, et al. Comprehensive analysis of SMAD4 mutations and protein expression in juvenile polyposis: Evidence for a distinct genetic pathway and polyp morphology in SMAD4 mutation carriers. Am J Pathol 2001;159:1293-1300.
15. Bertolino P, Deckers M, Lebrin F, ten Dijke P. Transforming growth factor-beta signal transduction in angiogenesis and vascular disorders. Chest 2005;128:585S-590S.
16. Marchuk DA, Srinivasan S, Squire TL, Zawistowski JS. Vascular morphogenesis: Tales of two syndromes. Hum Mol Genet 2003;12(Spec No 1): R97-R112.
17. Feng XH, Derynck R. A kinase subdomain of transforming growth factor-beta (TGF-beta) type I receptor determines the TGF-beta intracellular signaling specificity. EMBO J 1997;16:3912-3923.
18. Kimchi A, Wang XF, Weinberg RA, Cheifetz S, Massague J. Absence of TGF-beta receptors and growth inhibitory responses in retinoblastoma cells. Science 1988;240:196-199.
19. Mishra L, Derynck R, Mishra B. Transforming growth factor-beta signaling in stem cells and cancer. Science 2005;310:68-71.
20. De Matteis MA, Morrow JS. Spectrin tethers and mesh in the biosynthetic pathway. J Cell Sci 2000;113(Pt 13):2331-2343.
21. Tang Y, Katuri V, Dillner A, Mishra B, Deng CX, Mishra L. Disruption of transforming growth factor-beta signaling in ELF beta-spectrin-deficient mice. Science 2003;299:574-577.
22. Weinstein M, Monga SP, Liu Y, Brodie SG, Tang Y, Li C, et al. Smad proteins and hepatocyte growth factor control parallel regulatory pathways that converge on beta1-integrin to promote normal liver development. Mol Cell Biol 2001;21:5122-5131.
23. Mishra B, Tang Y, Katuri V, Fleury T, Said AH, Rashid A, et al. Loss of cooperative function of transforming growth factor-beta signaling proteins, smad3 with embryonic liver fodrin, a beta-spectrin, in primary biliary cirrhosis. Liver Int 2004;24:637-645.
24. Kitisin K, Ganesan N, Tang Y, Jogunoori W, Volpe EA, Kim SS, et al. Disruption of transforming growth factor-beta signaling through beta-spectrin ELF leads to hepatocellular cancer through cyclin D1 activation. Oncogene 2007;26:7103-7110.
25. Kim SS, Cao L, Lim SC, Li C, Wang RH, Xu X, et al. Hyperplasia and spontaneous tumor development in the gynecologic system in mice lacking the BRCA1-Delta11 isoform. Mol Cell Biol 2006;26:6983-6992.
26. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-254.
27. Mishra L, Cai T, Yu P, Monga SP, Mishra B. Elf3 encodes a novel 200-kD beta-spectrin: Role in liver development. Oncogene 1999;18:353-364.
28. Rahimi N, Dayanir V, Lashkari K. Receptor chimeras indicate that the vascular endothelial growth factor receptor-1 (VEGFR-1) modulates mitogenic activity of VEGFR-2 in endothelial cells. J Biol Chem 2000;275: 16986-16992.
29. Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Biochem Soc Trans 2003;31:20-24.
30. Gold LI. The role for transforming growth factor-beta (TGF-beta) in human cancer. Crit Rev Oncog 1999;10:303-360.
31. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med 2000;342:1350-1358.
32. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996;271:350-353.
33. Miyaki M, Kuroki T. Role of Smad4 (DPC4) inactivation in human cancer. Biochem Biophys Res Commun 2003;306:799-804.
34. Thiagalingam S, Lengauer C, Leach FS, Schutte M, Hahn SA, Overhauser J, et al. Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat Genet 1996;13:343-346.
35. Tang Y, Katuri V, Srinivasan R, Fogt F, Redman R, Anand G, et al. Transforming growth factor-beta suppresses nonmetastatic colon cancer through Smad4 and adaptor protein ELF at an early stage of tumorigenesis. Cancer Res 2005;65:4228-4237.
36. Katuri V, Tang Y, Li C, Jogunoori W, Deng CX, Rashid A, et al. Critical interactions between TGF-beta signaling/ELF, and E-cadherin/beta-catenin mediated tumor suppression. Oncogene 2006;25:1871-1886.
37. Liu F, Matsuura I. Inhibition of Smad antiproliferative function by CDK phosphorylation. Cell Cycle 2005;4:63-66.
38. Kim SS, Shetty K, Katuri V, Kitisin K, Baek HJ, Tang Y, et al. TGF-beta signaling pathway inactivation and cell cycle deregulation in the development of gastric cancer: Role of the beta-spectrin, ELF. Biochem Biophys Res Commun 2006;344:1216-1223.
39. Baek HJ, Kim SS, da Silva FM, Volpe EA, Evans S, Mishra B, et al. Inactivation of TGF-beta signaling in lung cancer results in increased CDK4 activity that can be rescued by ELF. Biochem Biophys Res Commun 2006;346:1150-1157.
40. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
41. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
42. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421-430.
43. Chow NH, Hsu PI, Lin XZ, Yang HB, Chan SH, Cheng KS, et al. Expression of vascular endothelial growth factor in normal liver and hepatocellular carcinoma: An immunohistochemical study. Hum Pathol 1997;28: 698-703.
44. Miura H, Miyazaki T, Kuroda M, Oka T, Machinami R, Kodama T, et al. Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma. J Hepatol 1997;27:854-861.
45. Yamaguchi R, Yano H, Iemura A, Ogasawara S, Haramaki M, Kojiro M. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. HEPATOLOGY 1998;28:68-77.
46. El-Assal ON, Yamanoi A, Soda Y, Yamaguchi M, Igarashi M, Yamamoto A, et al. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: Possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. HEPATOLOGY 1998;27:1554-1562.
47. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Yanase K, et al. Involvement of the vascular endothelial growth factor receptor-1 in murine hepatocellular carcinoma development. J Hepatol 2004;41:97-103.
48. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Hicklin DJ, et al. Halting the interaction between vascular endothelial growth factor and its receptors attenuates liver carcinogenesis in mice. HEPATOLOGY 2004;39: 1517-1524.
49. Kong SY, Park JW, Lee JA, Park JE, Park KW, Hong EK, et al. Association between vascular endothelial growth factor gene polymorphisms and survival in hepatocellular carcinoma patients. HEPATOLOGY 2007;46:446-455.